<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:f947160b-989b-400d-820e-c6a7ae22ffff"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="1dd71147-5ab6-4b22-b3d5-fa3fc38967b0"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-06-07T17:03:40Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:846326fa-3d87-47f5-ab18-9996c7980590"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="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"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 75 IU powder and solvent for solution for injection</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 1050 IU/1.75 mL powder and solvent for solution for injection</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCCCCC"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 450 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 450 IU/0.75 mL powder and solvent for solution for injection</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each vial contains 5.5 micrograms of follitropin alfa* equivalent to 75 IU. Each mL of the reconstituted solution contains 75 IU.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each multidose vial contains 87 micrograms of follitropin alfa* (equivalent to 1200 IU), in order to deliver 77 micrograms (equivalent to 1050 IU) in 1.75 mL. Each mL of the reconstituted solution contains 600 IU.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCCCCC"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 450 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each multidose vial contains 44 micrograms of follitropin alfa* (equivalent to 600 IU), in order to deliver 33 micrograms (equivalent to 450 IU) in 0.75 mL. Each mL of the reconstituted solution contains 600 IU.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">* recombinant human follicle stimulating hormone (rhFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black;background:#D9D9D9">Additionally &lt;GONAL-f 1050 IU&gt; </span></i><i><span lang="EN-GB" style="font-size: 11.0pt;color:black">+ <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span></span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;background:#D9D9D9"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Excipient with known effect:</span></u><span lang="EN-GB" style="font-size:11.0pt;color:black"> The reconstituted solution contains 9.45 mg benzyl alcohol per mL.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">For the full list of excipients, see section 6.1.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Powder and solvent for solution for injection.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Appearance of the powder: white lyophilised pellet.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Appearance of the solvent: clear colourless solution.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">The pH of the reconstituted solution is 6.57.5.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">In adult women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as <i>in vitro</i> fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level &lt; 1.2 IU/L.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">In adult men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin (hCG) therapy.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Treatment with GONAL-f should be initiated under the supervision of a physician experienced in the treatment of fertility disorders.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Posology</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">The dose recommendations given for GONAL-f are those in use for urinary FSH. Clinical assessment of GONALf indicates that its daily doses, regimens of administration, and treatment monitoring procedures should not be different from those currently used for urinary FSH-containing medicinal products. It is advised to adhere to the recommended starting doses indicated below.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Comparative clinical studies have shown that on average patients require a lower cumulative dose and shorter treatment duration with GONALf compared with urinary FSH. Therefore, it is considered appropriate to give a lower total dose of GONALf than generally used for urinary FSH, not only in order to optimise follicular development but also to minimise the risk of unwanted ovarian hyperstimulation. See section 5.1.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">Additional <span style="background:#D9D9D9">&lt;GONAL-f 1050 IU&gt;</span> + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Bioequivalence has been demonstrated between equivalent doses of the monodose presentation and the multidose presentation of GONAL-f.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">The following table states the volume to be administered to deliver the prescribed dose:</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"></p><div align="center"> <table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><b><span lang="EN-GB" style="font-size:   11.0pt;color:black">Dose (IU)</span></b></p> </td> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><b><span lang="EN-GB" style="font-size:   11.0pt;color:black">Volume to be injected (mL)</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">75</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.13</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">150</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.25</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">225</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.38</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">300</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.50</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">375</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.63</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">450</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.75</span></p> </td> </tr> </table> </div><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><b><span lang="EN-GB" style="font-size:   11.0pt;color:black">Dose (IU)</span></b></p> </td> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><b><span lang="EN-GB" style="font-size:   11.0pt;color:black">Volume to be injected (mL)</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">75</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.13</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">150</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.25</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">225</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.38</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">300</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.50</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">375</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.63</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:141.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">450</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormalIndent" style="margin-top:0in;margin-right:0in;margin-bottom:   0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;   line-height:normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:   11.0pt;color:black">0.75</span></p> </td> </tr> </table><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Women with anovulation (including polycystic ovarian syndrome)</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf may be given as a course of daily injections. In menstruating women treatment should commence within the first 7 days of the menstrual cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A commonly used regimen commences at 75150 IU FSH daily and is increased preferably by 37.5 or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate, but not excessive, response. Treatment should be tailored to the individual patients response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion. The maximal daily dose is usually not higher than 225 IU FSH. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned and the patient should undergo further evaluation after which she may recommence treatment at a higher starting dose than in the abandoned cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">When an optimal response is obtained, a single injection of 250 micrograms recombinant human choriogonadotropin alfa (rhCG) or 5,000 IU, up to 10,000 IU hCG should be administered 2448 hours after the last GONAL-f injection. The patient is recommended to have coitus on the day of, and the day following, hCG administration. Alternatively, intrauterine insemination (IUI) may be performed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">If an excessive response is obtained, treatment should be stopped and hCG withheld (see section 4.4). Treatment should recommence in the next cycle at a dose lower than that of the previous cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive technologies</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">A commonly used regimen for superovulation involves the administration of 150225 IU of GONALf daily, commencing on days 2 or 3 of the cycle. Treatment is continued until adequate follicular development has been achieved (as assessed by monitoring of serum oestrogen concentrations and/or ultrasound examination), with the dose adjusted according to the patients response, to usually not higher than 450 IU daily. In general, adequate follicular development is achieved on average by the tenth day of treatment (range 5 to 20 days).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A single injection of 250 micrograms rhCG or 5,000 IU up to 10,000 IU hCG is administered 2448 hours after the last GONAL-f injection to induce final follicular maturation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Down-regulation with a gonadotropin-releasing hormone (GnRH) agonist or antagonist is now commonly used in order to suppress the endogenous LH surge and to control tonic levels of LH. In a commonly used protocol, GONALf is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved. For example, following two weeks of treatment with an agonist, 150225 IU GONAL-f are administered for the first 7 days. The dose is then adjusted according to the ovarian response.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Overall experience with IVF indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Women with anovulation resulting from severe LH and FSH deficiency</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of GONALf therapy in association with lutropin alfa is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG). GONALf should be given as a course of daily injections simultaneously with lutropin alfa. Since these patients are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A recommended regimen commences at 75 IU of lutropin alfa daily with 75150 IU FSH. Treatment should be tailored to the individual patients response as assessed by measuring follicle size by ultrasound and oestrogen response.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 714 day intervals and preferably by 37.575 IU increments. It may be acceptable to extend the duration of stimulation in any one cycle to up to 5 weeks.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">When an optimal response is obtained, a single injection of 250 micrograms r-hCG or 5,000 IU up to 10,000 IU hCG should be administered 2448 hours after the last GONALf and lutropin alfa injections. The patient is recommended to have coitus on the day of, and on the day following, hCG administration. Alternatively, IUI may be performed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">If an excessive response is obtained, treatment should be stopped and hCG withheld. Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Men with hypogonadotrophic hypogonadism</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months. If after this period, the patient has not responded, the combination treatment may be continued; current clinical experience indicates that treatment for at least 18 months may be necessary to achieve spermatogenesis.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Special populations</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Elderly</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There is no relevant use of GONALf in the elderly population. Safety and effectiveness of GONALf in elderly patients have not been established.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Renal or hepatic impairment</span></u></i></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">Safety, efficacy and pharmacokinetics of GONALf in patients with renal or hepatic impairment have not been established.</span></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"></p><p class="MsoBodyText2" style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB">Paediatric population</span></u></i></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">There is no relevant use of GONAL-f in the paediatric population.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Method of administration</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is intended for subcutaneous use. The injection should be given at the same time each day.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The first injection of GONALf should be performed under direct medical supervision. Self-administration of GONALf should only be performed by patients who are well motivated, adequately trained and have access to expert advice.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">The injection site should be alternated daily.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black;background:#D9D9D9">&lt;GONAL-f 1050 IU&gt;</span></i><i><span lang="EN-GB" style="font-size:11.0pt; color:black"> + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">As GONAL-f multidose is intended for several injections, clear instructions should be provided to the patients to avoid misuse of the multidose presentation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Due to a local reactivity to benzyl alcohol, the same site of injection should not be used on consecutive days.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Individual reconstituted vials should be for single patient use only.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">For instructions on the reconstitution and administration of GONALf powder and solvent for solution for injection see section 6.6 and the package leaflet.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">hypersensitivity to the active substance or to any of the excipients listed in section 6.1</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">tumours of the hypothalamus or pituitary gland</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">gynaecological haemorrhages of unknown aetiology</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">ovarian, uterine or mammary carcinoma</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">GONAL-f must not be used when an effective response cannot be obtained, such as:</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">primary ovarian failure</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">malformations of sexual organs incompatible with pregnancy</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">fibroid tumours of the uterus incompatible with pregnancy</span></p><p align="left" class="MsoNormal" style="margin:0in;margin-bottom:.0001pt; text-align:left;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">primary testicular insufficiency</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Traceability</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><u><span lang="EN-GB" style="font-size:11.0pt">General recommendations</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is a potent gonadotrophic substance capable of causing mild to severe adverse reactions and should only be used by physicians who are thoroughly familiar with infertility problems and their management.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Gonadotropin therapy requires a certain time commitment by physicians and supportive health professionals, as well as the availability of appropriate monitoring facilities. In women, safe and effective use of GONALf calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis. There may be a degree of interpatient variability in response to FSH administration, with a poor response to FSH in some patients and exaggerated response in others. The lowest effective dose in relation to the treatment objective should be used in both men and women.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Porphyria</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Patients with porphyria or a family history of porphyria should be closely monitored during treatment with GONALf. Deterioration or a first appearance of this condition may require cessation of treatment.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Before starting treatment, the couples infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment given.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Patients undergoing stimulation of follicular growth, whether as treatment for anovulatory infertility or ART procedures, may experience ovarian enlargement or develop hyperstimulation. Adherence to recommended GONALf dose and regimen of administration and careful monitoring of therapy will minimise the incidence of such events. For accurate interpretation of the indices of follicle development and maturation, the physician should be experienced in the interpretation of the relevant tests.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In clinical trials, an increase of the ovarian sensitivity to GONALf was shown when administered with lutropin alfa. If an FSH dose increase is deemed appropriate, dose adaptation should preferably be at 714 day intervals and preferably with 37.5-75 IU increments.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">No direct comparison of GONALf/LH versus human menopausal gonadotropin (hMG) has been performed. Comparison with historical data suggests that the ovulation rate obtained with GONALf/LH is similar to that obtained with hMG.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><h3 style="margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt; margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal"><i><u><span lang="EN-GB" style="font-size:11.0pt;font-weight:normal">Ovarian Hyperstimulation Syndrome (OHSS)</span></u></i></h3><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A certain degree of ovarian enlargement is an expected effect of controlled ovarian stimulation. It is more commonly seen in women with polycystic ovarian syndrome and usually regresses without treatment.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with increasing degrees of severity. It comprises marked ovarian enlargement, high serum sex steroids, and an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal, pleural and, rarely, in the pericardial cavities.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The following symptomatology may be observed in severe cases of OHSS: abdominal pain, abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and gastrointestinal symptoms including nausea, vomiting and diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be complicated by ovarian torsion or thromboembolic events such as pulmonary embolism, ischaemic stroke or myocardial infarction.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Independent risk factors for developing OHSS include polycystic ovarian syndrome high absolute or rapidly rising serum oestradiol levels (e.g. &gt; 900 pg/mL or &gt; 3,300 pmol/L in anovulation; &gt; 3,000 pg/mL or &gt; 11,000 pmol/L in ART) and large number of developing ovarian follicles (e.g. &gt; 3 follicles of  14 mm in diameter in anovulation;  20 follicles of  12 mm in diameter in ART).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Adherence to recommended GONALf dose and regimen of administration can minimise the risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of stimulation cycles by ultrasound scans as well as oestradiol measurements are recommended to early identify risk factors.</span></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs. Therefore, if signs of ovarian hyperstimulation occur such as serum oestradiol level &gt; 5,500 pg/mL or &gt; 20,200 pmol/L and/or  40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days. OHSS may progress rapidly (within 24 hours) or over several days to become a serious medical event. It most often occurs after hormonal treatment has been discontinued and reaches its maximum at about seven to ten days following treatment. Therefore, patients should be followed for at least two weeks after hCG administration.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><a name="OLEII-109_Company_Response_to_LoQLINK4"></a><a name="OLEII-109_Company_Response_to_LoQLINK5"></a><span lang="EN-GB">In ART, aspiration of all follicles prior to ovulation may reduce the occurrence of hyperstimulation.</span></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Mild or moderate OHSS usually resolves spontaneously. If severe OHSS occurs, it is recommended that gonadotropin treatment be stopped if still ongoing, and that the patient be hospitalised and appropriate therapy be started.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Multiple pregnancy</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In patients undergoing ovulation induction, the incidence of multiple pregnancy is increased compared with natural conception. The majority of multiple conceptions are twins. Multiple pregnancy, especially of high order, carries an increased risk of adverse maternal and perinatal outcomes.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">To minimise the risk of multiple pregnancy, careful monitoring of ovarian response is recommended.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In patients undergoing ART procedures the risk of multiple pregnancy is related mainly to the number of embryos replaced, their quality and the patient age.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The patients should be advised of the potential risk of multiple births before starting treatment.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Pregnancy loss</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction or ART than following natural conception.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Ectopic pregnancy</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments. The prevalence of ectopic pregnancy after ART, was reported to be higher than in the general population.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Reproductive system neoplasms</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not yet established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Congenital malformation</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and multiple pregnancies.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Thromboembolic events</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events. In these women, the benefits of gonadotropin administration need to be weighed against the risks. It should be noted however that pregnancy itself as well as OHSS also carry an increased risk of thromboembolic events.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Elevated endogenous FSH levels are indicative of primary testicular failure. Such patients are unresponsive to GONALf/hCG therapy. GONAL-f should not be used when an effective response cannot be obtained.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Semen analysis is recommended 4 to 6 months after the beginning of treatment as part of the assessment of the response.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Sodium content</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially sodiumfree.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black;background:#D9D9D9">Additionally &lt;GONAL-f 1050 IU&gt; </span></i><i><span lang="EN-GB" style="font-size: 11.0pt;color:black">+ <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#D9D9D9"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Solvent containing benzyl alcohol</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#D9D9D9"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#D9D9D9"><span lang="EN-GB" style="font-size:11.0pt;color:black">Following reconstitution with the solvent provided, this medicinal product contains 1.23 mg benzyl alcohol in each 75 IU dose which is equivalent to 9.45 mg/mL. Benzyl alcohol may cause allergic reactions.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Concomitant use of GONAL-f with other medicinal products used to stimulate ovulation (e.g. hCG, clomiphene citrate) may potentiate the follicular response, whereas concurrent use of a GnRH agonist or antagonist to induce pituitary desensitisation may increase the dose of GONAL-f needed to elicit an adequate ovarian response. No other clinically significant medicinal product interaction has been reported during GONAL-f therapy.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Pregnancy</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There is no indication for use of GONAL-f during pregnancy. Data on a limited number of exposed pregnancies (less than 300 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity of follitropin alfa.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">No teratogenic effect has been observed in animal studies (see section 5.3).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of GONALf.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Breastfeeding</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is not indicated during breastfeeding.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Fertility</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoPlainText" style="margin-top:0in;text-align:left; line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>GONALf is indicated for use in infertility (see section 4.1).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is expected to have no or negligible influence on the ability to drive and use machines.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Summary of the safety profile</span></u></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Mild or moderate ovarian hyperstimulation syndrome (OHSS) has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon (see section 4.4).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Thromboembolism may occur very rarely (see section 4.4).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">List of adverse reactions</span></u></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The following definitions apply to the frequency terminology used hereafter: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Immune system disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Very rare:                Mild to severe hypersensitivity reactions including anaphylactic reactions and shock</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Nervous system disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very common:         Headache</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Vascular disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very rare:                Thromboembolism (both in association with and separate from OHSS)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Respiratory, thoracic and mediastinal disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very rare:                Exacerbation or aggravation of asthma</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><u><span lang="EN-GB" style="font-size: 11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Gastrointestinal disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Common:                Abdominal pain, abdominal distension, abdominal discomfort, nausea, vomiting, diarrhoea</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Reproductive system and breast disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very common:         Ovarian cysts</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Common:                Mild or moderate OHSS (including associated symptomatology)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Uncommon:            Severe OHSS (including associated symptomatology) (see section 4.4)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Rare:                       Complication of severe OHSS</span></p><p class="Formatvorlage1" style="margin-left:92.15pt;text-indent:-92.15pt; line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">General disorders and administration site conditions</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very common:         Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Immune system disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very rare:                Mild to severe hypersensitivity reactions including anaphylactic reactions and shock</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><i><u><span lang="EN-GB" style="font-size:11.0pt">Respiratory, thoracic and mediastinal disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very rare:                Exacerbation or aggravation of asthma</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><u><span lang="EN-GB" style="font-size: 11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Skin and subcutaneous tissue disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Common:                Acne</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Reproductive system and breast disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Common:                Gynaecomastia, varicocele</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">General disorders and administration site conditions</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:92.15pt;margin-bottom:.0001pt;text-align:left; text-indent:-92.15pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Very common:         Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Investigations</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Common:                Weight gain</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;text-autospace:none"><u><span lang="EN-GB" style="font-size:11.0pt">Reporting of suspected adverse reactions</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;text-autospace:none"><span lang="EN-GB" style="font-size:11.0pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the <span style="color:black;background:#D9D9D9">national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="font-size:11.0pt;background:#D9D9D9">Appendix V</span></a></span><span lang="EN-GB" style="font-size:11.0pt">.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The effects of an overdose of GONAL-f are unknown, nevertheless, there is a possibility that OHSS may occur (see section 4.4).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Pharmacotherapeutic group: Sex hormones and modulators of the genital systems, gonadotropins, ATC code: G03GA05.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;text-autospace:none"><span lang="EN-GB" style="font-size:11.0pt">In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.</span><a name="OLEII-109_Company_Response_to_LoQLINK16"></a><span lang="EN-GB" style="font-size:11.0pt">In women with anovulation, the object of GONAL-f therapy is to develop a single mature Graafian follicle from which the ovum will be liberated after the administration of hCG.</span><a name="OLEII-109_Company_Response_to_LoQLINK17"></a></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Clinical efficacy and safety in women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum LH level &lt; 1.2 IU/L as measured in a central laboratory. However, it should be taken into account that there are variations between LH measurements performed in different laboratories.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In clinical studies comparing rhFSH (follitropin alfa) and urinary FSH in ART (see table below) and in ovulation induction, GONALf was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In ART, GONAL-f at a lower total dose and shorter treatment period than urinary FSH, resulted in a higher number of oocytes retrieved when compared to urinary FSH.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Table: Results of study GF 8407 (randomised parallel group study comparing efficacy and safety of GONALf with urinary FSH in assisted reproduction technologies)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:19.6pt;border-collapse:collapse;border:none"> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="Titlefortables" style="margin:0in;text-indent:0in;line-height:normal"></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Titlefortables" style="margin:0in;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">GONAL-f<br/>   (n = 130)</span></p> </td> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Titlefortables" style="margin:0in;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">urinary FSH</span><span lang="EN-GB" style="font-size:11.0pt"> <br/>   (n = 116)</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">Number of oocytes retrieved</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">11.0  5.9</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">8.8  4.8</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">Days of FSH stimulation required</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">11.7  1.9</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">14.5  3.3</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">Total dose of FSH required (number of FSH 75 IU ampoules) </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">27.6  10.2</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">40.7  13.6</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Need to   increase the dose (%)</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">56.2</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">85.3</span></p> </td> </tr> </table><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Differences between the 2 groups were statistically significant (p&lt; 0.05) for all criteria listed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Clinical efficacy and safety in men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In men deficient in FSH, GONALf administered concomitantly with hCG for at least 4 months induces spermatogenesis.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day. The steady state volume of distribution and total clearance are 10 L and 0.6 L/h, respectively. Oneeighth of the follitropin alfa dose is excreted in the urine.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Following subcutaneous administration, the absolute bioavailability is about 70%. Following repeated administration, follitropin alfa accumulates 3fold achieving a steadystate within 34 days. In women whose endogenous gonadotropin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity and genotoxicity additional to that already stated in other sections of this SmPC.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">A<i>dditional in &lt;GONAL-f 1050 IU&gt; + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </i></span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">In rabbits, the formulation reconstituted with 0.9% benzyl alcohol and 0.9% benzyl alcohol alone, both resulted in a slight haemorrhage and subacute inflammation after single subcutaneous injection or mild inflammatory and degenerative changes after single intramuscular injection respectively.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Impaired fertility has been reported in rats exposed to pharmacological doses of follitropin alfa ( 40 IU/kg/day) for extended periods, through reduced fecundity.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Given in high doses ( 5 IU/kg/day) follitropin alfa caused a decrease in the number of viable foetuses without being a teratogen, and dystocia similar to that observed with urinary Menopausal Gonadotropin (hMG). However, since GONAL-f is not indicated in pregnancy, these data are of limited clinical relevance.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="Formatvorlage1" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Powder</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Sucrose</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Sodium dihydrogen phosphate monohydrate</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Disodium phosphate dihydrate</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Methionine</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Polysorbate 20</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Phosphoric acid, concentrated</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Sodium hydroxide</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Solvent</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Water for injections</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt; + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Powder</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Sucrose</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Sodium dihydrogen phosphate monohydrate</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Disodium phosphate dihydrate</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Phosphoric acid, concentrated</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Sodium hydroxide</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Solvent</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Water for injections</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Benzyl alcohol</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt; + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> <span style="background:#A6A6A6">&gt;</span></span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F2F2F2"><span lang="EN-GB" style="font-size:11.0pt;color:black">3 years.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">For immediate and single use following first opening and reconstitution.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt; + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">2 years.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">The reconstituted solution is stable for 28 days at or below 25C.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Do not store above 25C.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Store in the original package, in order to protect from light.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt; + <span style="background:#BFBFBF">&lt;GONAL-f 450 IU&gt;</span> </span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">Prior to reconstitution, do not store above 25C. Store in the original package, in order to protect from light.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">After reconstitution, do not store above 25C. Do not freeze. Store in the original container, in order to protect from light.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F2F2F2"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONALf is presented as a powder and solvent for injection. The powder is presented in 3 mL vials (Type I glass), with rubber stopper (bromobutyl rubber) and aluminium flipoff cap. The 1 mL solvent for reconstitution is presented in 1 mL prefilled syringes (Type I glass) with a rubber stopper.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F2F2F2"></p><p align="left" class="MsoCommentText" style="margin-top:0in;text-align:left; line-height:normal;background:#F2F2F2"><span lang="EN-GB" style="font-size:11.0pt; color:black">The medicinal product is supplied in packs of 1, 5, or 10 vials with 1, 5 or 10 of solvent pre-filled syringes.</span></p><p align="left" class="MsoCommentText" style="margin-top:0in;text-align:left; line-height:normal;background:#F2F2F2"><span lang="EN-GB" style="font-size:11.0pt; color:black">Not all pack sizes may be marketed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL f is presented as a powder and solvent for injection. The powder is presented in 3 mL vials (Type I glass), with rubber stopper (bromobutyl rubber) and aluminium flipoff cap. The solvent for reconstitution is presented in 2 mL prefilled syringes (Type I glass) with a rubber stopper. The administration syringes made of polypropylene with a stainless steel pre-fixed needle are also provided.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">The medicinal product is supplied as a pack of 1 vial of powder with 1 prefilled syringe of solvent for reconstitution and 15 disposable syringes for administration graduated in FSH units.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCCCCC"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 450 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL f is presented as a powder and solvent for injection. The powder is presented in 3 mL vials (Type I glass), with rubber stopper (bromobutyl rubber) and aluminium flipoff cap. The solvent for reconstitution is presented in 1 mL prefilled syringes (Type I glass) with a rubber stopper. The administration syringes made of polypropylene with a stainless steel pre-fixed needle are also provided.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">The medicinal product is supplied as a pack of 1 vial of powder with 1 prefilled syringe of solvent for reconstitution and 6 disposable syringes for administration graduated in FSH units.</span></p><h2 style="margin:0in;margin-bottom:.0001pt;text-indent:0in;line-height:normal; page-break-after:auto"></h2>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">For single use only.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f must be reconstituted with the solvent before use (see section How to prepare and use the GONAL-f powder and solvent in the package leaflet).</span></p><p class="Formatvorlage1" style="line-height:normal;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f may be co-reconstituted with lutropin alfa and co-administered as a single injection. In this case lutropin alfa should be reconstituted first and then used to reconstitute GONAL-f powder.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="EN-GB" style="font-size:11.0pt;color:black">Studies have shown that co-administration with lutropin alfa, does not significantly alter the activity, stability, pharmacokinetic nor pharmacodynamic properties of the active substances.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#E6E6E6"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 1050 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 1050 IU/1.75 mL powder must be reconstituted with the 2 mL solvent provided before use.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 1050 IU/1.75 mL powder must not be reconstituted with any other GONAL-f containers.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#E6E6E6"><span lang="EN-GB" style="font-size:11.0pt;color:black">The solvent pre-filled syringe provided should be used for reconstitution only and then disposed of in accordance with local requirements. A set of administration syringes graduated in FSH units is supplied in the GONAL-f multidose box. Alternatively, a 1 mL syringe, graduated in mL, with prefixed needle for subcutaneous administration could be used (see section How to prepare and use the GONALf powder and solvent in the package leaflet).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCCCCC"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 450 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 450 IU/0.75 mL powder be reconstituted with the 1 mL solvent provided before use.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 450 IU/0.75 mL powder must not be reconstituted with any other GONAL-f containers.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCCCCC"><span lang="EN-GB" style="font-size:11.0pt;color:black">The solvent pre-filled syringe provided should be used for reconstitution only and then disposed of in accordance with local requirements. A set of administration syringes graduated in FSH units is supplied in the GONAL-f multidose box. Alternatively, a 1 mL syringe, graduated in mL, with prefixed needle for subcutaneous administration could be used (see section How to prepare and use the GONALf powder and solvent in the package leaflet).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The reconstituted solution should not be administered if it contains particles or is not clear.</span></p><p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Merck Europe B.V.</span></p><p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Gustav Mahlerplein 102</span></p><p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">1082 MA Amsterdam</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The Netherlands</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/025</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/026</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/027</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#F3F3F3"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 75 IU&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/025</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/026</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#F3F3F3"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/027</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Date of first authorisation: 20 October 1995.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Date of latest renewal: 20 October 2010.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Detailed information on this medicinal product is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu/"><span style="font-size:11.0pt">http://www.ema.europa.eu</span></a></span><span lang="EN-GB" style="font-size:11.0pt">.</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#D5DCE4"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f <span style="background:yellow">150</span> IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;background:#D5DCE4"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f <span style="background:yellow">150 IU/0.25</span> mL solution for injection in pre-filled pen</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCFFFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 300 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCFFFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 300 IU/0.5 mL solution for injection in pre-filled pen</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCECFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 450 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCECFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 450 IU/0.75 mL solution for injection in pre-filled pen</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#99CCFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 900 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#99CCFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 900 IU/1.5 mL solution for injection in pre-filled pen</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Each mL of the solution contains 600 IU of follitropin alfa* (equivalent to 44 micrograms).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#D5DCE4"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f <span style="background:yellow">150</span> IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#D5DCE4"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each pre-filled multidose pen delivers <span style="background:yellow">150</span> IU (equivalent to <span style="background:yellow">11</span> micrograms) in <span style="background: yellow">0.25</span> mL.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCFFFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 300 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;background:#CCFFFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each pre-filled multidose pen delivers 300 IU (equivalent to 22 micrograms) in 0.5 mL.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#CCECFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 450 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;background:#CCECFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each pre-filled multidose pen delivers 450 IU (equivalent to 33 micrograms) in 0.75 mL.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#99CCFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 900 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;background:#99CCFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">Each pre-filled multidose pen delivers 900 IU (equivalent to 66 micrograms) in 1.5 mL.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">* recombinant human follicle stimulating hormone (rhFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">For the full list of excipients, see section 6.1.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Solution for injection in pre-filled pen.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Clear colourless solution.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">The pH of the solution is 6.77.3.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">In adult women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as <i>in vitro</i> fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level &lt; 1.2 IU/L.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">In adult men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin (hCG) therapy.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Treatment with GONAL-f should be initiated under the supervision of a physician experienced in the treatment of fertility disorders.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">Patients must be provided with the correct number of pens for their treatment course and educated to use the proper injection techniques.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Posology</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">The dose recommendations given for GONAL-f are those in use for urinary FSH. Clinical assessment of GONAL-f indicates that its daily doses, regimens of administration, and treatment monitoring procedures should not be different from those currently used for urinary FSH-containing medicinal products. It is advised to adhere to the recommended starting doses indicated below.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Comparative clinical studies have shown that on average patients require a lower cumulative dose and shorter treatment duration with GONAL-f compared with urinary FSH. Therefore, it is considered appropriate to give a lower total dose of GONAL-f than generally used for urinary FSH, not only in order to optimise follicular development but also to minimise the risk of unwanted ovarian hyperstimulation. See section 5.1.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Bioequivalence has been demonstrated between equivalent doses of the monodose presentation and the multidose presentation of GONAL-f.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Women with anovulation (including polycystic ovarian syndrome)</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf may be given as a course of daily injections. In menstruating women treatment should commence within the first 7 days of the menstrual cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A commonly used regimen commences at 75150 IU FSH daily and is increased preferably by 37.5 or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate, but not excessive, response. Treatment should be tailored to the individual patients response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion. The maximal daily dose is usually not higher than 225 IU FSH. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned and the patient should undergo further evaluation after which she may recommence treatment at a higher starting dose than in the abandoned cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">When an optimal response is obtained, a single injection of 250 micrograms recombinant human choriogonadotropin alfa (rhCG) or 5,000 IU, up to 10,000 IU hCG should be administered 2448 hours after the last GONAL-f injection. The patient is recommended to have coitus on the day of, and the day following, hCG administration. Alternatively, intrauterine insemination (IUI) may be performed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">If an excessive response is obtained, treatment should be stopped and hCG withheld (see section 4.4). Treatment should recommence in the next cycle at a dose lower than that of the previous cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive technologies</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">A commonly used regimen for superovulation involves the administration of 150225 IU of GONALf daily, commencing on days 2 or 3 of the cycle. Treatment is continued until adequate follicular development has been achieved (as assessed by monitoring of serum oestrogen concentrations and/or ultrasound examination), with the dose adjusted according to the patients response, to usually not higher than 450 IU daily. In general, adequate follicular development is achieved on average by the tenth day of treatment (range 5 to 20 days).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A single injection of 250 micrograms rhCG or 5,000 IU up to 10,000 IU hCG is administered 2448 hours after the last GONALf injection to induce final follicular maturation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Down-regulation with a gonadotropin-releasing hormone (GnRH) agonist or antagonist is now commonly used in order to suppress the endogenous LH surge and to control tonic levels of LH. In a commonly used protocol, GONALf is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved. For example, following two weeks of treatment with an agonist, 150225 IU GONALf are administered for the first 7 days. The dose is then adjusted according to the ovarian response.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Overall experience with IVF indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Women with anovulation resulting from severe LH and FSH deficiency</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of GONALf therapy in association with lutropin alfa is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG). GONALf should be given as a course of daily injections simultaneously with lutropin alfa. Since these patients are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A recommended regimen commences at 75 IU of lutropin alfa daily with 75150 IU FSH. Treatment should be tailored to the individual patients response as assessed by measuring follicle size by ultrasound and oestrogen response.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 714 day intervals and preferably by 37.575 IU increments. It may be acceptable to extend the duration of stimulation in any one cycle to up to 5 weeks.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">When an optimal response is obtained, a single injection of 250 micrograms r-hCG or 5,000 IU up to 10,000 IU hCG should be administered 2448 hours after the last GONALf and lutropin alfa injections. The patient is recommended to have coitus on the day of, and on the day following, hCG administration. Alternatively, IUI may be performed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">If an excessive response is obtained, treatment should be stopped and hCG withheld. Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Men with hypogonadotrophic hypogonadism</span></u></i></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">GONALf should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months. If after this period, the patient has not responded, the combination treatment may be continued; current clinical experience indicates that treatment for at least 18 months may be necessary to achieve spermatogenesis.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Special populations</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Elderly</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There is no relevant use of GONALf in the elderly population. Safety and effectiveness of GONALf in elderly patients have not been established.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Renal or hepatic impairment</span></u></i></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">Safety, efficacy and pharmacokinetics of GONALf in patients with renal or hepatic impairment have not been established.</span></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"></p><p class="MsoBodyText2" style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB">Paediatric population</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There is no relevant use of GONALf in the paediatric population.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Method of administration</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is intended for subcutaneous use. The injection should be given at the same time each day.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The first injection of GONALf should be performed under direct medical supervision. Self-administration of GONALf should only be performed by patients who are well motivated, adequately trained and have access to expert advice.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">As GONALf pre-filled pen with multidose cartridge is intended for several injections, clear instructions should be provided to the patients to avoid misuse of the multidose presentation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">For instructions on the administration with the pre-filled pen, see section 6.6 and the Instructions for use.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">hypersensitivity to the active substance or to any of the excipients listed in section 6.1</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">tumours of the hypothalamus or pituitary gland</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">gynaecological haemorrhages of unknown aetiology</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">ovarian, uterine or mammary carcinoma</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">GONAL-f must not be used when an effective response cannot be obtained, such as:</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">primary ovarian failure</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">malformations of sexual organs incompatible with pregnancy</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">fibroid tumours of the uterus incompatible with pregnancy</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol"></span><span lang="EN-GB" style="font-size:11.0pt">primary testicular insufficiency</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Traceability</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">General recommendations</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is a potent gonadotrophic substance capable of causing mild to severe adverse reactions and should only be used by physicians who are thoroughly familiar with infertility problems and their management.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Gonadotropin therapy requires a certain time commitment by physicians and supportive health professionals, as well as the availability of appropriate monitoring facilities. In women, safe and effective use of GONALf calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis. There may be a degree of interpatient variability in response to FSH administration, with a poor response to FSH in some patients and exaggerated response in others. The lowest effective dose in relation to the treatment objective should be used in both men and women.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Porphyria</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Patients with porphyria or a family history of porphyria should be closely monitored during treatment with GONALf. Deterioration or a first appearance of this condition may require cessation of treatment.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Before starting treatment, the couples infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment given.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Patients undergoing stimulation of follicular growth, whether as treatment for anovulatory infertility or ART procedures, may experience ovarian enlargement or develop hyperstimulation. Adherence to recommended GONALf dose and regimen of administration and careful monitoring of therapy will minimise the incidence of such events. For accurate interpretation of the indices of follicle development and maturation, the physician should be experienced in the interpretation of the relevant tests.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In clinical trials, an increase of the ovarian sensitivity to GONALf was shown when administered with lutropin alfa. If an FSH dose increase is deemed appropriate, dose adaptation should preferably be at 714 day intervals and preferably with 37.5-75 IU increments.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">No direct comparison of GONALf/LH versus human menopausal gonadotropin (hMG) has been performed. Comparison with historical data suggests that the ovulation rate obtained with GONALf/LH is similar to that obtained with hMG.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><h3 style="margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt; margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal"><i><u><span lang="EN-GB" style="font-size:11.0pt;font-weight:normal">Ovarian Hyperstimulation Syndrome (OHSS)</span></u></i></h3><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">A certain degree of ovarian enlargement is an expected effect of controlled ovarian stimulation. It is more commonly seen in women with polycystic ovarian syndrome and usually regresses without treatment.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with increasing degrees of severity. It comprises marked ovarian enlargement, high serum sex steroids, and an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal, pleural and, rarely, in the pericardial cavities.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The following symptomatology may be observed in severe cases of OHSS: abdominal pain, abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and gastrointestinal symptoms including nausea, vomiting and diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be complicated by ovarian torsion or thromboembolic events such as pulmonary embolism, ischaemic stroke or myocardial infarction.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Independent risk factors for developing OHSS include polycystic ovarian syndrome high absolute or rapidly rising serum oestradiol levels (e.g. &gt; 900 pg/mL or &gt; 3,300 pmol/L in anovulation; &gt; 3,000 pg/mL or &gt; 11,000 pmol/L in ART) and large number of developing ovarian follicles (e.g. &gt; 3 follicles of  14 mm in diameter in anovulation;  20 follicles of  12 mm in diameter in ART).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Adherence to recommended GONALf dose and regimen of administration can minimise the risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of stimulation cycles by ultrasound scans as well as oestradiol measurements are recommended to early identify risk factors.</span></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs. Therefore, if signs of ovarian hyperstimulation occur such as serum oestradiol level &gt; 5,500 pg/mL or &gt; 20,200 pmol/L and/or  40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days. OHSS may progress rapidly (within 24 hours) or over several days to become a serious medical event. It most often occurs after hormonal treatment has been discontinued and reaches its maximum at about seven to ten days following treatment. Therefore, patients should be followed for at least two weeks after hCG administration.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoBodyText2" style="margin-top:0in;line-height:normal"><span lang="EN-GB">In ART, aspiration of all follicles prior to ovulation may reduce the occurrence of hyperstimulation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Mild or moderate OHSS usually resolves spontaneously. If severe OHSS occurs, it is recommended that gonadotropin treatment be stopped if still ongoing, and that the patient be hospitalised and appropriate therapy be started.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Multiple pregnancy</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In patients undergoing ovulation induction, the incidence of multiple pregnancy is increased compared with natural conception. The majority of multiple conceptions are twins. Multiple pregnancy, especially of high order, carries an increased risk of adverse maternal and perinatal outcomes.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">To minimise the risk of multiple pregnancy, careful monitoring of ovarian response is recommended.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In patients undergoing ART procedures the risk of multiple pregnancy is related mainly to the number of embryos replaced, their quality and the patient age.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The patients should be advised of the potential risk of multiple births before starting treatment.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Pregnancy loss</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction or ART than following natural conception.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Ectopic pregnancy</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments. The prevalence of ectopic pregnancy after ART, was reported to be higher than in the general population.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Reproductive system neoplasms</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not yet established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Congenital malformation</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and multiple pregnancies.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Thromboembolic events</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events. In these women, the benefits of gonadotropin administration need to be weighed against the risks. It should be noted however that pregnancy itself as well as OHSS also carry an increased risk of thromboembolic events.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Elevated endogenous FSH levels are indicative of primary testicular failure. Such patients are unresponsive to GONALf/hCG therapy. GONAL-f should not be used when an effective response cannot be obtained.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Semen analysis is recommended 4 to 6 months after the beginning of treatment as part of the assessment of the response.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Sodium content</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially sodium-free.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Concomitant use of GONAL-f with other medicinal products used to stimulate ovulation (e.g. hCG, clomiphene citrate) may potentiate the follicular response, whereas concurrent use of a GnRH agonist or antagonist to induce pituitary desensitisation may increase the dose of GONAL-f needed to elicit an adequate ovarian response. No other clinically significant medicinal product interaction has been reported during GONAL-f therapy.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Pregnancy</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">There is no indication for use of GONAL-f during pregnancy. Data on a limited number of exposed pregnancies (less than 300 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity of follitropin alfa.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">No teratogenic effect has been observed in animal studies (see section 5.3).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of GONALf.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Breastfeeding</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is not indicated during breastfeeding.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Fertility</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoPlainText" style="margin-top:0in;text-align:left; line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>GONAL-f is indicated for use in infertility (see section 4.1).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">GONALf is expected to have no or negligible influence on the ability to drive and use machines.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Summary of the safety profile</span></u></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Mild or moderate ovarian hyperstimulation syndrome (OHSS) has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon (see section 4.4).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Thromboembolism may occur very rarely (see section 4.4).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt">List of adverse reactions</span></u></p><p class="MsoNormal" style="margin-top:0in;line-height:normal;page-break-after: avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The following definitions apply to the frequency terminology used hereafter: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Immune system disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very rare:           Mild to severe hypersensitivity reactions including anaphylactic reactions and shock</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><u><span lang="EN-GB" style="font-size: 11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Nervous system disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very common:    Headache</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Vascular disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very rare:           Thromboembolism (both in association with and separate from OHSS)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Respiratory, thoracic and mediastinal disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very rare:           Exacerbation or aggravation of asthma</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><u><span lang="EN-GB" style="font-size: 11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Gastrointestinal disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Common:           Abdominal pain, abdominal distension, abdominal discomfort, nausea, vomiting, diarrhoea</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Reproductive system and breast disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very common:    Ovarian cysts</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:77.95pt;margin-bottom:.0001pt;text-align:left; text-indent:-77.95pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Common:           Mild or moderate OHSS (including associated symptomatology)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Uncommon:        Severe OHSS (including associated symptomatology) (see section 4.4)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:77.95pt;margin-bottom:.0001pt;text-align:left; text-indent:-77.95pt;line-height:normal"><span lang="EN-GB" style="font-size: 11.0pt">Rare:                  Complication of severe OHSS</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">General disorders and administration site conditions</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very common:    Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Treatment in men</span></u></p><p class="Formatvorlage1" style="margin-left:78.0pt;text-indent:-78.0pt; line-height:normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Immune system disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very rare:           Mild to severe hypersensitivity reactions including anaphylactic reactions and shock</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Respiratory, thoracic and mediastinal disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very rare:           Exacerbation or aggravation of asthma</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Skin and subcutaneous tissue disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Common:           Acne</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Reproductive system and breast disorders</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Common:           Gynaecomastia, varicocele</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">General disorders and administration site conditions</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Very common:    Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><u><span lang="EN-GB" style="font-size: 11.0pt"></span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt">Investigations</span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:78.0pt;margin-bottom:.0001pt;text-align:left; text-indent:-78.0pt;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Common:           Weight gain</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;text-autospace:none"><u><span lang="EN-GB" style="font-size:11.0pt">Reporting of suspected adverse reactions</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;text-autospace:none"><span lang="EN-GB" style="font-size:11.0pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the <span style="color:black;background:#D9D9D9">national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="font-size:11.0pt;background:#D9D9D9">Appendix V</span></a></span><span lang="EN-GB" style="font-size:11.0pt">.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The effects of an overdose of GONAL-f are unknown, nevertheless, there is a possibility that OHSS may occur (see section 4.4).</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Pharmacotherapeutic group: Sex hormones and modulators of the genital systems, gonadotropins, ATC code: G03GA05.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;text-autospace:none"><span lang="EN-GB" style="font-size:11.0pt">In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.</span><span lang="EN-GB" style="font-size:11.0pt"> In women with anovulation, the object of GONAL-f therapy is to develop a single mature Graafian follicle from which the ovum will be liberated after the administration of hCG.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Clinical efficacy and safety in women</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum LH level &lt; 1.2 IU/L as measured in a central laboratory. However, it should be taken into account that there are variations between LH measurements performed in different laboratories.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In clinical studies comparing rhFSH (follitropin alfa) and urinary FSH in ART (see table below) and in ovulation induction, GONALf was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In ART, GONAL-f at a lower total dose and shorter treatment period than urinary FSH, resulted in a higher number of oocytes retrieved when compared to urinary FSH.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Table: Results of study GF 8407 (randomised parallel group study comparing efficacy and safety of GONALf with urinary FSH in assisted reproduction technologies)</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:26.7pt;border-collapse:collapse;border:none"> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="Titlefortables" style="margin:0in;text-indent:0in;line-height:normal"></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Titlefortables" style="margin:0in;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">GONAL-f<br/>   (n = 130)</span></p> </td> <td style="width:106.35pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p class="Titlefortables" style="margin:0in;text-indent:0in;line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">urinary FSH</span><span lang="EN-GB" style="font-size:11.0pt"> <br/>   (n = 116)</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">Number of oocytes retrieved</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">11.0  5.9</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">8.8  4.8</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">Days of FSH stimulation required</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">11.7  1.9</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">14.5  3.3</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">Total dose of FSH required (number of FSH 75 IU ampoules) </span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">27.6  10.2</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:   11.0pt">40.7  13.6</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">Need to   increase the dose (%)</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">56.2</span></p> </td> <td style="width:106.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;   line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">85.3</span></p> </td> </tr> </table><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Differences between the 2 groups were statistically significant (p&lt; 0.05) for all criteria listed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Clinical efficacy and safety in men</span></u></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">In men deficient in FSH, GONALf administered concomitantly with hCG for at least 4 months induces spermatogenesis.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day. The steady state volume of distribution and total clearance are 10 L and 0.6 L/h, respectively. Oneeighth of the follitropin alfa dose is excreted in the urine.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Following subcutaneous administration, the absolute bioavailability is about 70%. Following repeated administration, follitropin alfa accumulates 3fold achieving a steadystate within 34 days. In women whose endogenous gonadotropin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity and genotoxicity additional to that already stated in other sections of this SmPC.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Impaired fertility has been reported in rats exposed to pharmacological doses of follitropin alfa ( 40 IU/kg/day) for extended periods, through reduced fecundity.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Given in high doses ( 5 IU/kg/day) follitropin alfa caused a decrease in the number of viable foetuses without being a teratogen, and dystocia similar to that observed with urinary Menopausal Gonadotropin (hMG). However, since GONAL-f is not indicated in pregnancy, these data are of limited clinical relevance.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Poloxamer 188</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Sucrose</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Methionine</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Sodium dihydrogen phosphate monohydrate</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Disodium phosphate dihydrate</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">m-Cresol</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Phosphoric acid, concentrated</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Sodium hydroxide</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Water for injections</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Not applicable.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">2 years.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Once opened, the medicinal product may be stored for a maximum of 28 days at or below 25C. The patient should write on the GONAL-f pre-filled pen the day of the first use.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Store in a refrigerator (2C8C). Do not freeze.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Before opening and within its shelf life, the medicinal product may be removed from the refrigerator, without being refrigerated again, for up to 3 months at or below 25C. The product must be discarded if it has not been used after 3 months.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Store in the original package, in order to protect from light.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">For in-use storage conditions, see section 6.3.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#D5DCE4"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f <span style="background:yellow">150</span> IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#D5DCE4"><span lang="EN-GB" style="font-size:11.0pt;color:black;background:yellow">0.25</span><span lang="EN-GB" style="font-size:11.0pt;color:black"> mL of solution for injection in 3 mL cartridge (Type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a black rubber inlay.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#D5DCE4"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#D5DCE4"><span lang="EN-GB" style="font-size:11.0pt;color:black">Pack of one pre-filled pen and <span style="background:yellow">4 needles</span> to be used with the pen for administration.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCFFFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 300 IU  PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCFFFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">0.5 mL of solution for injection in 3 mL cartridge (Type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a black rubber inlay.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCFFFF"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCFFFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">Pack of one pre-filled pen and 8 needles to be used with the pen for administration.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCECFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black;background:#CCECFF">&lt;GONAL-f 450 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCECFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">0.75 mL of solution for injection in 3 mL cartridge (Type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a black rubber inlay.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCECFF"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCECFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">Pack of one pre-filled pen and 12 needles to be used with the pen for administration.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#99CCFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 900 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#99CCFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">1.5 mL of solution for injection in 3 mL cartridge (Type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a black rubber inlay.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#99CCFF"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#99CCFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">Pack of one pre-filled pen and 20 needles to be used with the pen for administration.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">See the Instructions for use.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The solution should not be administered if it contains particles or is not clear.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Any unused solution must be discarded not later than 28 days after first opening.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#D5DCE4"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f <span style="background:yellow">150</span> IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#D5DCE4"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f <span style="background:yellow">150 IU/0.25</span> mL solution for injection in pre-filled pen is not designed to allow the cartridge to be removed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCFFFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 300 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCFFFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 300 IU/0.5 mL solution for injection in pre-filled pen is not designed to allow the cartridge to be removed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCECFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black;background:#CCECFF">&lt;GONAL-f 450 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCECFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 450 IU/0.75 mL solution for injection in pre-filled pen is not designed to allow the cartridge to be removed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#99CCFF"><i><span lang="EN-GB" style="font-size:11.0pt;color:black">&lt;GONAL-f 900 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#99CCFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">GONAL-f 900 IU/1.5 mL solution for injection in pre-filled pen is not designed to allow the cartridge to be removed.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Discard used needles immediately after injection.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Merck Europe B.V.</span></p><p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Gustav Mahlerplein 102</span></p><p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">1082 MA Amsterdam</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">The Netherlands</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;margin-right:0in; margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left; text-indent:-28.35pt;line-height:normal;page-break-after:avoid;background:#D5DCE4"><i><span lang="FR" style="font-size:11.0pt;color:black">&lt;GONAL-f <span style="background:yellow">150</span> IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#D5DCE4"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/<span style="background:yellow">000</span></span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCFFFF"><i><span lang="FR" style="font-size:11.0pt;color:black">&lt;GONAL-f 300 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCFFFF"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/033</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#CCECFF"><i><span lang="FR" style="font-size:11.0pt;color:black;background:#CCECFF">&lt;GONAL-f 450 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#CCECFF"><span lang="FR" style="font-size:11.0pt;color:black">EU/1/95/001/034</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid;background:#99CCFF"><i><span lang="FR" style="font-size:11.0pt;color:black">&lt;GONAL-f 900 IU PEN&gt;</span></i></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;background:#99CCFF"><span lang="EN-GB" style="font-size:11.0pt;color:black">EU/1/95/001/035</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Date of first authorisation: 20 October 1995.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Date of latest renewal: 20 October 2010.</span></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal;page-break-after:avoid"></p><p align="left" class="MsoNormal" style="margin-top:0in;text-align:left;line-height: normal"><span lang="EN-GB" style="font-size:11.0pt">Detailed information on this medicinal product is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu/"><span style="font-size:11.0pt">http://www.ema.europa.eu</span></a></span><span lang="EN-GB" style="font-size:11.0pt">.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>